Literature DB >> 8585865

Effects of dofetilide on electrical dispersion and arrhythmias in post-infarcted anesthetized dogs.

A J D'Alonzo1, J C Sewter, R B Darbenzio, T A Hess.   

Abstract

An increase in dispersion of myocardial refractoriness has been shown to coincide with a greater risk of inducible ventricular arrhythmias. We compared the dispersion of electrophysiologic parameters and antiarrhythmic effects of dofetilide (0.03, 0.1, 0.3 and 1 mg/kg i.v.) in post-infarcted anesthetized dogs. Animals were tested for inducibility of arrhythmias using a programmed electrical stimulation (PES) protocol, and divided into inducible (I) and non-inducible (NI) groups. In addition, myocardial vulnerability was measured using ventricular fibrillation thresholds (VFT), as well as susceptibility to sudden cardiac death (SCD). Dofetilide significantly increased ventricular effective refractory periods (ERP) and monophasic action potential durations (APD) in a dose-dependent manner. The standard deviation of ERP, which was used as an index of dispersion of refractoriness, increased from sham (control value of 5.4 +/- sd 2.5 ms), non-inducible (control value of 11.0 +/- 5.5 and 8.0 +/- 3.7 ms for vehicle and dofetilide groups, respectively) and inducible states (control value of 17.3 +/- 6.2 and 21.6 +/- 7.1 ms for vehicle and dofetilide groups, respectively). However, dofetilide treatment did not alter dispersion of refractoriness over the dose range studied. Dofetilide did not significantly increase inducibility in the NI group (2 out of 8 [25%] compared to 0 out of 9 [0%] in vehicle treated animals). In the I group, dofetilide (0.3 mg/kg) treated animals converted 2 out of 7 (29%) to NI, and 5 out of 7 (71%; significant at p < 0.05) to a NI or non sustained ventricular tachycardia. There were no significant changes in VFT following the last dose of dofetilide given. Dofetilide did not significantly affect SCD survival (88% and 29% in the NI and I group, respectively) relative to vehicle (66% and 50% in the NI and I group, respectively). Although infarct sizes were significantly greater in the I groups, there was no difference between vehicle and dofetilide animals within these groups. In conclusion, dofetilide increased ERP and APD values, but did not affect dispersion of refractoriness. Thus, changes in dispersion of refractoriness may be used as a marker for inducibility in untreated animals, but it did not predict the antiarrhythmic effects observed with dofetilide.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8585865     DOI: 10.1007/bf00788505

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  34 in total

1.  Ventricular fibrillation threshold; its physiological and pharmacological importance.

Authors:  E N Moore; J F Spear
Journal:  Arch Intern Med       Date:  1975-03

2.  Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide.

Authors:  E Carmeliet
Journal:  J Pharmacol Exp Ther       Date:  1992-08       Impact factor: 4.030

3.  Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents.

Authors:  M C Sanguinetti; N K Jurkiewicz
Journal:  J Gen Physiol       Date:  1990-07       Impact factor: 4.086

4.  Effects of phentolamine on electrophysiologic properties of isolated canine purkinje fibers.

Authors:  M R Rosen; H Gelband; B F Hoffman
Journal:  J Pharmacol Exp Ther       Date:  1971-12       Impact factor: 4.030

5.  Comparative effects of beta-adrenergic blocking drugs on experimental ventricular fibrillation threshold.

Authors:  J L Anderson; H E Rodier; L S Green
Journal:  Am J Cardiol       Date:  1983-04       Impact factor: 2.778

6.  Reentrant ventricular arrhythmias in the late myocardial infarction period. 9. Electrophysiologic-anatomic correlation of reentrant circuits.

Authors:  R Mehra; R H Zeiler; W B Gough; N El-Sherif
Journal:  Circulation       Date:  1983-01       Impact factor: 29.690

7.  Arrhythmia inducibility and ventricular vulnerability in a chronic feline infarction model.

Authors:  L Wetstein; R Mark; G J Kelliher; T Friehling; K M O'Connor; P R Kowey
Journal:  Am Heart J       Date:  1985-11       Impact factor: 4.749

8.  Effects of WAY-123,398, a new class III antiarrhythmic agent, on cardiac refractoriness and ventricular fibrillation threshold in anesthetized dogs: a comparison with UK-68798, E-4031, and dl-sotalol.

Authors:  W Spinelli; R W Parsons; T J Colatsky
Journal:  J Cardiovasc Pharmacol       Date:  1992-12       Impact factor: 3.105

9.  Reentrant ventricular arrhythmias in the late myocardial infarction period in the dog. 13. Correlation of activation and refractory maps.

Authors:  W B Gough; R Mehra; M Restivo; R H Zeiler; N el-Sherif
Journal:  Circ Res       Date:  1985-09       Impact factor: 17.367

10.  Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris.

Authors:  M L Sedgwick; H S Rasmussen; S M Cobbe
Journal:  Am J Cardiol       Date:  1992-12-01       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.